Survival from testicular cancer in England and Wales up to 2001 by Huddart, R A
Clinical Commentary
Survival from testicular cancer in England and Wales up to 2001
RA Huddart*,1
1The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK
British Journal of Cancer (2008) 99, S83–S85. doi:10.1038/sj.bjc.6604598 www.bjcancer.com
Published online 23 September 2008
& 2008 Cancer Research UK
                
For many years testicular cancer has been the prime example of the
tumour that is chemocurable, even when metastatic. The
disappointment in oncology is that these results have so far not
been replicated in the more common solid tumours. Why this
should be is not clear but germ-cell tumours retain sensitivity to
chemotherapy in vitro and a number of mechanisms including
reduced DNA repair capacity and proneness to apoptosis have
been proposed (Mayer et al, 2003).
Most patients with testicular cancer present after finding a lump
in the testicle that may or may not be painful. A small proportion
of patients present with symptoms of metastatic disease. With the
exception of some patients with metastatic disease, initial
treatment after first assessment is to remove the tumour by
inguinal orchidectomy. Patients are staged by tumour marker
estimation and CT scan. In most patients (60–70%) no further
evidence of disease is found. These patients are still at risk of
relapse and are managed by careful observation or by adminis-
tration of low toxicity adjuvant therapy. For patients with
metastatic disease the mainstay of treatment is combination
chemotherapy. Though some patients were cured as early as the
1960s with chemotherapy (Table 1) it was the advent of cisplatin in
the late 1970s and then etoposide in the early 1980s, which
transformed the prognosis of the disease. Together with bleomy-
cin, these two drugs make up the gold standard chemotherapy
schedule for testicular cancer, BEP. This schedule, first developed
in the early 1980s, rapidly superseded previous treatments and has
not been improved on since in any randomised studies.
Perhaps it is a surprise, then, that there has been continued
improvement in survival since the 1980s through to the late 1990s
with commensurate improvement in older patients and in the
socially deprived. Why should this be when the chemotherapy
(BEP) used is essentially the same as in the early 1980s?
One explanation is likely to be earlier presentation of patients,
resulting from improved education and awareness of testicular
cancer in both patients and their doctors. Since the early 1990s
several charities such as The Everyman Campaign and Cancer
Research UK have been vocal in raising the awareness and profile
of testicular cancer, with evidence that the general population
are both more aware of testicular cancer and practice testicular
self-examination.
This has been coupled with recent targets to see new patients
within 2 weeks and operate within a further 4 weeks. In a review of
our testicular database at the Royal Marsden the median time from
symptoms to orchidectomy has fallen for Stage I non-seminoma-
tous germ-cell tumours (NSGCT) and seminoma from 79 and 70.5
days, respectively, in 1970–1974 to 54 and 41 days in 1995–1999
(Po0.05 comparing 1995–1999 with the rest; Alan Horwich,
unpublished observations; Figure 1). Similar results have been
reported from Yorkshire when the average time of symptoms to
GP vists reduced from 5 to 2 weeks (Vasudev et al, 2004).
In a rapidly growing tumour like TGCT it would be anticipated
that reductions in presentation delays would lead to reduced
tumour size and earlier stage at diagnosis, findings recently
reported both in the United Kingdom (Bhardwa et al, 2005) and
Europe (Sonneveld et al, 1999; Lackner et al, 2006). In the UK
study from St Bartholomew’s Hospital in London the average
tumour size at presentation has fallen from 4cm in 1984–1995 to
2.5cm between 1999 and 2002 (P¼0.002) whereas over the same
time periods, the proportion of patients with Stage I disease
increased from 57 to 77% (Figure 1). This is important as Stage I
patients have anticipated survival rates in excess of 99% (Schmoll
et al, 2004) and within Stage I, seminoma size is an important
prognostic factor for subsequent relapse (Warde et al, 2002). In
addition, and anecdotally, several major UK centres have reported
fewer patients with most advanced prognostic metastatic disease
(Bhala et al, 2004).
Stage migration may be one explanation for improved survival
but even in those presenting with metastatic disease there has been
some suggestion of improved outcomes. Mead et al (1997)
reported a pooled analysis of patients with NSGCT and seminoma
who were largely treated in the 1980s. This study defined
prognostic categories. For NSGCT the good prognosis group had
an expected 5-year survival of 91%, intermediate prognosis of
79% and poor prognosis of 48%. These have become the
internationally accepted benchmark survival figures. Several
reports have suggested improved outcomes over time (Sonneveld
et al, 2001; Bhala et al, 2004) and (Muramaki et al, 2004) with the
greatest improvements being seen in the poorer prognostic groups.
For instance, in the report from Bhala et al from Sheffield the
5-year survival between 1989 and 2001 for good, intermediate and
poor prognostic patients was 95, 82 and 57% respectively. A number
of reports using more intensive chemotherapy have reported even
better results in poor prognosis patients with survival rates exceeding
75% (Bower et al, 1997; Christian et al, 2003).
Why should survival improve in these patient groups? Some
groups as noted above, have used more intensive treatment but
these approaches are yet to show improved survival over standard
BEP treatment in randomised trials. Over this time period there
has been increased awareness of the importance of dose intensity,
reduction in the use of carboplatin, which was common in the
1980s but shown to be less active in randomised trials (Horwich
et al, 1997) and improved supportive care, for example, antibiotic
care and use of growth factors. This has been associated with a *Correspondence: Dr RA Huddart; E-mail: robert.huddart@icr.ac.uk
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based on data that patients treated in larger specialist centres fair
better than patients treated elsewhere (Harding et al, 1993; Collette
et al, 1999). The report of Collette et al, who showed, within the
context of a EORTC/MRC randomised trial that centres recruiting
five or more patients had better survival than centres recruiting
fewer patients (2-year survival 77 vs 62%; HR¼1.85; P¼0.01), is
particularly important. A number of possible explanations were
highlighted in this paper: patients from the larger recruiting centre
having trends for a higher dose intensity, fewer treatment delays,
lower toxic death rate (6 vs 13%) and more surgical resections (65
vs 52%). This report and an earlier study from the west of Scotland
(Harding et al, 1993) with similar results have driven the
movement to increased centralization of both surgical and non-
surgical management. It is now recommended in the United
Kingdom that testicular cancer services are delivered by networks
with not less than 2 million population.
Where do we go from here? There is some scope to improve
outcomes for the most socially deprived sections of the community,
to achieve the results equivalent to the wealthiest sections of our
population. We do also have to start thinking of the longer term:
Not what the outcome is over 5 or 10 years but over a lifetime in
this young group of patients. Recent reports of increased late
cardiac morbidity and second malignancy (Huddart, 2003; Zagars
et al, 2004; Travis et al, 2005) in long-term survivors are a concern.
This means we have to start to look at our current strategies to
minimise these risks. We do not want to win this battle and lose
the war.
SUMMARY
The improved outcomes for UK testicular cancer patients should
be welcomed. This is likely to be because of earlier diagnosis,
standardisation of treatment, treatment in specialist centres and
improved supportive care. Further study should focus on ensuring
that the best standards of care are available to the entire
population and to minimise the very long-term risks of treatment.
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Figure 1 Changes in delays in diagnosis, tumour size and stage at presentation over time. Based on unpublished observations from the Royal Marsden
testicular tumour database and data on tumour size and stage at presentation data from St Bartholomew’s Hospital, London (Bhardwa et al, 2005).
Table 1 Progress in chemotherapy schedules for testicular cancer; outcomes from chemotherapy in metastatic disease
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